Merit Medical is finishing a three-year operating program under its first non-founder chief executive, and the mid-year print is the first clean look at whether that program still compounds after Fred Lampropoulos left the board. Organic constant-currency sales rose 9%, the fastest quarterly pace in three years, and management lifted full-year revenue and adjusted earnings guidance. The equity debate is narrower than a simple growth-versus-value argument. It is whether the rebound is the new run-rate or a mix of tariff refunds, tuck-in deals, and a seasonal catch-up that fades once the Continued Growth Initiatives window closes at year-end.
The tension sits in the quality of the beat. Domestic hospital demand and the Therapeutic book carried the quarter, while Foundational Access still leans on Biolife hemostasis and a DualCap line that Merit already sold. A tariff refund of almost $7 million fattened gross margin. A DualCap disposal gain padded first-half other income. Strip those items and the operating story is still better, just less dramatic. Inventory build also absorbed cash, so free cash flow lagged last year's first half even as earnings rose.
Guidance now points to roughly $1.6 billion of sales. Adjusted earnings sit in a band just above $4 a share. Shares near $85 imply roughly twenty times that midpoint. The question the second half has to settle is whether Therapeutic mix and organic growth hold once the refund is gone and the founder-era catalog review starts cutting as well as adding.